Clinical trials
catalyst calendar across sponsors →Studies where CGC is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
9 interventional · 1 observational
Held by 11 tracked-famous managers (JANE STREET GROUP, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, MILLENNIUM MANAGEMENT LLC, D. E. Shaw & Co., Inc., Verition Fund Management LLC, +6 more) · FINRA short interest 10.9 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 7 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Canadian Registry for the Use of Spectrum Therapeutics Cannabis Products in Subjects With Chronic PainNCT04763252observationalPhysician selection of Spectrum Therapeutics (ST) medical cannabis treatment regimen and changes over timeStudy Protocol ↗ | — | Unknown status | Other: Spectrum Therapeutics cannabis products | Chronic Pain | 500 | 2023-07-30 | 2022-08-15 |
| A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effects of CBN With and Without CBD on Sleep QualityNCT05839964Median sleep quality rating during the IP administration phase (measured with the Consensus Sleep Diary - Core Version completed within 1 hour of awakening each morning).Randomized · Triple-masked · Treatment | Phase 1/2 | Completed | Dietary supplement: CBN and CBD | Healthy Adults | 301 | 2022-12-06actual | 2023-05-03 |
| CBD in Postmenopausal Women With OsteopeniaNCT05317013Safety and Tolerability: Adverse Events/Serious Adverse EventsRandomized · Triple-masked · Supportive care | Phase 1 | Terminatedsponsor's stated reason: Low enrollment | Drug: CBD · Other: Placebo | Osteopenia | 2 | 2022-09-22actual | 2022-09-23 |
| Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CHI-915 in Healthy ParticipantsNCT05210634Incidence, type and severity of AEs/SAEsRandomized · Triple-masked · Other | Phase 1 | Completed | Dietary supplement: THCv | Healthy Adults | 21 | 2022-05-06actual | 2022-05-13 |
| Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Support Recovery From Physical ActivityNCT05026164Changes from baseline in blood pressure (mmHg) [Safety and Tolerability]Randomized · Triple-masked · Other | Phase 2 | Completed | Dietary supplement: CHI-202, CHI-101 | Delayed Onset Muscle Soreness (DOMS) | 40 | 2022-02-04actual | 2022-02-16 |
| The Effects of CBD Isolate on Menstrual-Related SymptomsNCT05679830Menstrual-Related Symptoms Questionnaire (MRSQ)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Cannabidiol | Menstrual Discomfort | 33 | 2021-09-23actual | 2023-01-11 |
| CHI-907 CBD Extract and Experiences of Test AnxietyNCT04269252Optimal single-dose of CHI-907 to reduce test anxietyRandomized · Double-masked · Other | Phase 2 | Terminatedsponsor's stated reason: Recruitment challenges due to COVID | Other: CHI-907, CHI-804 | Anxiety | 32 | 2021-06-01actual | 2021-06-04 |
| A Randomized Controlled Test of the Effects of CHI-554 on Fear.NCT04577612Fear ratingsRandomized · Double-masked · Prevention | Phase 2 | Completed | Drug: CHI-554 | Anxiety, Fear, Panic | 84 | 2021-05-15actual | 2021-06-03 |
| CHI-902 for Treatment of Social Anxiety DisorderNCT04086342Liebowitz Social Anxiety Scale (LSAS)Randomized · Double-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Changes in pipeline | Drug: CHI-902, Placebo | Social Anxiety Disorder | 0 | 2021-01-26 | 2020-06-04 |
| Investigation of the Efficacy and Safety of CHI-921 in Insomnia.NCT03984604Change from baseline of PSG latency to persistent sleepRandomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: COVID-19 | Drug: CHI-921, Placebo | Insomnia | 21 | 2020-06-17actual | 2020-10-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19